IndustryCompany release

Orthofix trims 2026 sales guidance to $825M–$830M as U.S. spine declines

🇺🇸 Orthofix Medical Inc. (OFIX) · Mon 09 Nov 2026

The medical device maker reported third-quarter net sales of $207.9M and an adjusted EBITDA of $26.0M, while U.S. spine sales fell 4.3%.

Orthofix Medical has lowered its full-year 2026 outlook, according to its November 2026 investor presentation. The company now expects net sales of $825M–$830M and adjusted EBITDA of $86M–$88M, with the guidance stated as of 9 November 2026.

For the third quarter, net sales were $207.9M, a 2% increase on a pro forma, constant-currency basis compared with the same period a year earlier. Adjusted EBITDA for the quarter came to $26.0M.

Growth was recorded in the limb reconstruction and therapeutic solutions businesses. U.S. spine was the weak spot, with sales down 4.3%, and the company's revised guidance follows that shortfall.

Orthofix also said it is working to improve free cash flow. The summary of the presentation provides no further detail on how, and the full source text was not available for this report.

What it means for your team

  • Market-access and commercial teams tracking Orthofix should note that the weakness is concentrated in U.S. spine, while limb reconstruction and therapeutic solutions grew.
  • Supplier and partner teams may wish to review planning assumptions against the revised guidance of $825M–$830M in net sales.
  • The available information contains no regulatory, quality or safety developments, so there is no direct pharmacovigilance or compliance implication.

Company's press release (SEC filing): Orthofix Medical Inc. ↗

Article written by VigiEye from the official source (Orthofix Medical Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →